摘要
目的:分析国内文献米氮平与选择性5-羟色胺再摄取抑制剂(SSRI)治疗抑郁症引发性功能障碍的差异。方法:用关键词从中国生物医学数据库光盘检索,采用固定效应模型(FEM)法对符合纳入标准的米氮平与SSRI治疗抑郁症的随机对照研究文献中药物引发性功能障碍的差异进行Meta分析。结果:14项研究例数1108例,其中研究组556例,对照组552例,米氮平治疗组发生性功能障碍5例,SSRI治疗组发生性功能障碍106例,两组性功能障碍的发生率分别是0.90%和19.2%,综合检验两组差异有统计学意义,Z=8.03,P<0.01;OR=0.07,95%CI:0.04～0.14。结论:在治疗抑郁症中,SSRI比米氮平更容易引发性功能障碍,应特别加以关注。
Objective： To compare the incidences of sexual dysfunction induced by mirtazapine and SSRI in the treatment of patients with depression. Methods ： Using key-word retrieval from the compact disks of the Chinese biological medicine （CBM） data base, we analyzed the rates of sexual dysfunction from the published clinical control trials on depression treated with mirtazapine and SSRI by ap- plying the fixed effects model （FEM） of evidence-based medicine （EBM）. Results： Among 1 108 cases in 14 studies, there were 5 cases of mirtazapine-induced and 106 cases of SSRI-induced sexual dysfunction, accounting for 0.90% and 19.2% respectively, OR =0.07 （95% CI： 0.04-0. 14）, Z = 8.03, P 〈 0.01. Conclusion： SSRI is far more likely to induce sexual dysfunction than mirtazapine in the treatment of depression. Natl J Androl, 2008, 14 （10） ： 896-899
出处
《中华男科学杂志》
CAS
CSCD
2008年第10期896-899,共4页
National Journal of Andrology
